Nattokinase Experimentally Eliminates 84% of Amyloid Microclots — a Pathology Recently Found in 100% of COVID-19 Vaccinated Individuals Tested
Epidemiologist Nicolas Hulscher on The Daily Pulse with Maria Zeee
A new peer-reviewed study found that every single COVID-19 vaccinated participant examined had Thioflavin-T–positive, fibrinolysis-resistant amyloid microclots circulating in their blood.
https://www.thefocalpoints.com/p/breaking-study-anomalous-amyloid
These misfolded fibrin clots are structurally abnormal, resistant to normal breakdown, and capable of accumulating inflammatory molecules, DNA, and other debris. They are likely also behind the long, rubbery, white fibrous clots that embalmers are pulling out of bodies worldwide.
But for the first time, there is real hope.
A breakthrough in-vitro study has shown that nattokinase — a natural enzyme from fermented soybeans — dissolves 84% of amyloid microclots within two hours, while also reducing overall clot burden and amyloid intensity. Even at lower doses, it produced large, dose-dependent reductions in total clot numbers and amyloid signal.
Nattokinase is safe, inexpensive, and orally bioavailable. It reaches systemic circulation and can theoretically interact with circulating amyloids.
It has dual-action activity, meaning it not only breaks down microclots but also degrades spike protein itself — the very trigger that forms these clots.
No hospital-grade clot-buster has shown this level of direct activity on misfolded fibrin.
This gives us the first plausible biochemical pathway to reduce amyloid burden in living individuals.
https://www.globalresearch.ca/nattokinase-eliminates-84-amyloid-microclots/5906788